William Blair Analysts Lift Earnings Estimates for MRSN

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Equities researchers at William Blair increased their Q3 2025 earnings per share estimates for shares of Mersana Therapeutics in a report released on Wednesday, August 13th. William Blair analyst A. Hsieh now expects that the company will earn ($0.60) per share for the quarter, up from their previous forecast of ($4.75). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. William Blair also issued estimates for Mersana Therapeutics’ Q4 2025 earnings at ($3.54) EPS, FY2025 earnings at ($1.99) EPS, Q1 2026 earnings at ($3.50) EPS, Q2 2026 earnings at ($3.47) EPS, Q3 2026 earnings at ($3.43) EPS, Q4 2026 earnings at ($3.40) EPS, FY2026 earnings at ($13.81) EPS and FY2027 earnings at ($14.74) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Wednesday, August 13th. The company reported ($4.08) earnings per share for the quarter, missing the consensus estimate of ($3.75) by ($0.33). The business had revenue of $3.06 million for the quarter, compared to analyst estimates of $6.06 million. Mersana Therapeutics had a negative return on equity of 990.16% and a negative net margin of 212.94%.

Several other research analysts also recently commented on the company. BTIG Research reissued a “buy” rating and issued a $17.00 price objective on shares of Mersana Therapeutics in a research note on Wednesday. Truist Financial reduced their price objective on Mersana Therapeutics from $250.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday. Wall Street Zen downgraded Mersana Therapeutics to a “strong sell” rating in a research note on Saturday, August 2nd. Wedbush reissued an “outperform” rating and issued a $75.00 price objective on shares of Mersana Therapeutics in a research note on Thursday, May 15th. Finally, Guggenheim reduced their price objective on Mersana Therapeutics from $125.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, Mersana Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $56.60.

Mersana Therapeutics Stock Performance

NASDAQ MRSN opened at $7.16 on Friday. The business has a fifty day moving average price of $8.05 and a 200 day moving average price of $9.96. Mersana Therapeutics has a one year low of $5.21 and a one year high of $70.75. The company has a market cap of $35.74 million, a P/E ratio of -0.49 and a beta of 0.83.

Institutional Trading of Mersana Therapeutics

Several large investors have recently added to or reduced their stakes in MRSN. Pallas Capital Advisors LLC purchased a new stake in Mersana Therapeutics in the 1st quarter valued at $33,000. JPMorgan Chase & Co. grew its holdings in Mersana Therapeutics by 156.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 130,094 shares of the company’s stock valued at $39,000 after buying an additional 79,390 shares in the last quarter. Invesco Ltd. grew its holdings in Mersana Therapeutics by 109.3% in the 1st quarter. Invesco Ltd. now owns 114,863 shares of the company’s stock valued at $40,000 after buying an additional 59,991 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Mersana Therapeutics in the 1st quarter valued at $45,000. Finally, Algert Global LLC grew its holdings in Mersana Therapeutics by 124.7% in the 1st quarter. Algert Global LLC now owns 135,013 shares of the company’s stock valued at $46,000 after buying an additional 74,930 shares in the last quarter. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.